Skip to Content

Multihance (gadobenate dimeglumine) Disease Interactions

There are 5 disease interactions with Multihance (gadobenate dimeglumine):

Major

Gadolinium based contrast agents (applies to Multihance) nephrogenic systemic fibrosis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Gadolinium based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Use of these agents should be avoided in these patients unless the diagnostic information is essential and unavailable with non- contrasted MRI or other diagnostic modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. The risk of NSF appears to be higher in patients with chronic severe renal disease and patients with acute kidney injury. Patients should be screened for acute renal injury and other conditions that might affect renal function such as age >60 years old, hypertension, and diabetes.

Major

Gadolinium-based contrast agents (applies to Multihance) renal impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Diabetes Mellitus, Hypertension

Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Gadobenate ion is eliminated predominately via the kidneys. The risk for NSF appears highest among patients with chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or acute kidney injury. It is recommended to avoid the use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other processes. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. Consider screening patients for acute kidney injury and other conditions that may reduce renal function and for patients at risk for chronically reduced renal function (e.g., age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. For patients receiving hemodialysis, physicians may consider the prompt initiation of hemodialysis following the administration of a GBCA to enhance the contrast agent's elimination. The usefulness of hemodialysis in the prevention of NSF is unknown.

Moderate

Gadobenate (applies to Multihance) arrhythmias

Moderate Potential Hazard, Moderate plausibility.

The use of gadobenate may cause cardiac arrhythmias. It is recommended to assess patients for underlying conditions or medications that predispose to arrhythmias.

Moderate

Gadolinium-based contrast agents (applies to Multihance) asthma

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Allergies

Patients with history of bronchial asthma might have an increased risk for a hypersensitivity reaction to gadolinium-based contrast agents. Patients should always be assessed for any history of a reaction to contrast media, asthma or other allergic disorders before the administration of these agents.

Moderate

Gadolinium-based contrast agents (applies to Multihance) visualization

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

The use of certain Gadolinium-based contrast agents (GBCAs) in patients with severe renal or hepatic impairment may impair imaging performance. If GBCAs are used in these patients, complete MRI no later than 60 minutes after GBCAs administration and use a paired non-contrast and contrast MRI set for diagnosis. It is recommended to exercise caution when interpreting contrast MR images in the absence of companion non-contrast MR images

Multihance (gadobenate dimeglumine) drug interactions

There are 50 drug interactions with Multihance (gadobenate dimeglumine)

Multihance (gadobenate dimeglumine) alcohol/food interactions

There is 1 alcohol/food interaction with Multihance (gadobenate dimeglumine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.